ABBOTT INDIA Financial Statement Analysis
|
||
|
The Revenues of ABBOTT INDIA have increased by 9.58% YoY .
The Earnings Per Share (EPS) of ABBOTT INDIA has increased by 9.73 % YoY. |
||
ABBOTT INDIA Last 5 Annual Financial Results
[BOM: 500488|NSE : ABBOTINDIA]
| Standalone | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹6,409 Cr | ₹5,849 Cr | ₹5,349 Cr | ₹4,913 Cr | ₹4,310 Cr |
| Expenses | ₹4,717 Cr | ₹4,396 Cr | ₹4,143 Cr | ₹3,832 Cr | ₹3,391 Cr |
| Operating Profit (Excl OI) | ₹1,692 Cr | ₹1,453 Cr | ₹1,205 Cr | ₹1,082 Cr | ₹919 Cr |
| Other Income | ₹278 Cr | ₹248 Cr | ₹154 Cr | ₹83 Cr | ₹83 Cr |
| Interest | ₹11 Cr | ₹12 Cr | ₹16 Cr | ₹19 Cr | ₹18 Cr |
| Depreciation | ₹72 Cr | ₹71 Cr | ₹70 Cr | ₹66 Cr | ₹58 Cr |
| Profit Before Tax | ₹1,887 Cr | ₹1,618 Cr | ₹1,274 Cr | ₹1,080 Cr | ₹926 Cr |
| Profit After Tax | ₹1,414 Cr | ₹1,201 Cr | ₹949 Cr | ₹799 Cr | ₹691 Cr |
| Earnings Per Share (Rs) | ₹730.36 | ₹665.62 | ₹565.28 | ₹446.78 | ₹375.86 |
| PAT Margin (%) | 21.88 | 21.43 | 19.88 | 17.29 | 15.89 |
| ROE(%) | 34.67 | 35.98 | 35.31 | 32.07 | 29.95 |
| ROCE(%) | 46.72 | 47.87 | 47.34 | 42.93 | 40.53 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 55,968.0 Cr |
| Revenue (TTM) | : | ₹ 7,004.4 Cr |
| Net Profit(TTM) | : | ₹ 1,614.7 Cr |
| EPS (TTM) | : | ₹ 761.6 |
| P/E (TTM) | : | 34.7 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ABBOTT INDIA | -4.4% | -8.3% | -17.8% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -3.3% | 15.7% |
| DIVIS LABORATORIES | 0.3% | 16.3% | 44.3% |
| TORRENT PHARMACEUTICALS | 2.8% | -0.5% | 37.1% |
| CIPLA | -3.1% | -1.2% | -5.8% |
| DR REDDYS LABORATORIES | -2.9% | -3% | -3.3% |
| MANKIND PHARMA | -1.1% | -7.2% | -1.7% |
| LUPIN | -1.8% | -11.7% | 14.5% |
| ZYDUS LIFESCIENCES | -5.8% | -3.4% | 16.8% |
ABBOTT INDIA Revenues
[BOM: 500488|NSE : ABBOTINDIA]
| Y-o-Y | 9.58 % |
| 5 Yr CAGR | 10.43 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹6,409 Cr | 9.58 | |
| Mar2025 | ₹5,849 Cr | 9.35 | |
| Mar2024 | ₹5,349 Cr | 8.86 | |
| Mar2023 | ₹4,913 Cr | 14.00 | |
| Mar2022 | ₹4,310 Cr | - | |
ABBOTT INDIA Operating Profit
[BOM: 500488|NSE : ABBOTINDIA]
| Y-o-Y | 16.45 % |
| 5 Yr CAGR | 16.49 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,692 Cr | 16.45 | |
| Mar2025 | ₹1,453 Cr | 20.54 | |
| Mar2024 | ₹1,205 Cr | 11.46 | |
| Mar2023 | ₹1,082 Cr | 17.71 | |
| Mar2022 | ₹919 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 6.28 % |
| 5 Yr CAGR | 5.49 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 26.4% | 6.28 | |
| Mar2025 | 24.84% | 10.20 | |
| Mar2024 | 22.54% | 2.41 | |
| Mar2023 | 22.01% | 3.24 | |
| Mar2022 | 21.32% | - | |
ABBOTT INDIA Profit After Tax
[BOM: 500488|NSE : ABBOTINDIA]
| Y-o-Y | 17.75 % |
| 5 Yr CAGR | 19.63 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,414 Cr | 17.75 | |
| Mar2025 | ₹1,201 Cr | 26.52 | |
| Mar2024 | ₹949 Cr | 18.87 | |
| Mar2023 | ₹799 Cr | 15.64 | |
| Mar2022 | ₹691 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 2.10 % |
| 5 Yr CAGR | 8.33 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 21.88 % | 2.10 | |
| Mar2025 | 21.43 % | 7.80 | |
| Mar2024 | 19.88 % | 14.98 | |
| Mar2023 | 17.29 % | 8.81 | |
| Mar2022 | 15.89 % | - | |
ABBOTT INDIA Earnings Per Share (EPS)
[BOM: 500488|NSE : ABBOTINDIA]
| Y-o-Y | 9.73 % |
| 5 Yr CAGR | 18.07 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹730 | 9.73 | |
| Mar2025 | ₹666 | 17.75 | |
| Mar2024 | ₹565 | 26.52 | |
| Mar2023 | ₹447 | 18.87 | |
| Mar2022 | ₹376 | - | |
ABBOTT INDIA Return on Capital Employed (ROCE)
[BOM: 500488|NSE : ABBOTINDIA]
| Y-o-Y | -2.40 % |
| 5 Yr CAGR | 3.62 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 46.72% | -2.40 | |
| Mar2025 | 47.87% | 1.12 | |
| Mar2024 | 47.34% | 10.27 | |
| Mar2023 | 42.93% | 5.92 | |
| Mar2022 | 40.53% | - | |
ABBOTT INDIA Share Price vs Sensex
| Current Share Price | : | ₹26,400.0 |
| Current MarketCap | : | ₹ 55,968.0 Cr |
| Updated EOD on | : | Aug 19,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ABBOTT INDIA | -4.4% |
-8.3% |
-17.8% |
| SENSEX | -1.4% |
-1% |
-4.6% |
ABBOTT INDIA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 150 MIDCAP INDEX | -0.6% | 1% | 10.3% |
| BSE 400 MIDSMALLCAP INDEX | -0.6% | 1% | 9.5% |
| BSE HEALTHCARE | -0.7% | 0.5% | 15.9% |
| BSE 200 EQUAL WEIGHT | -0.8% | 0.7% | 9.1% |
| BSE 1000 | -1% | 0.4% | 3.6% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDSMALL INDIA CONSUMPTION | -0.7% | -0.5% | -2.1% |
| NIFTY MIDSMALLCAP400 50:50 | -0.7% | 1.1% | NA |
| NIFTY MIDSMALLCAP 400 | -0.8% | 1% | 10.5% |
| NIFTY 500 EQUAL WEIGHT | -0.8% | 0.7% | 8.1% |
| NIFTY MIDCAP 150 | -0.9% | 1% | 11.1% |
You may also like the below Video Courses
FAQ about ABBOTT INDIA Financials
How the annual revenues of ABBOTT INDIA have changed ?
The Revenues of ABBOTT INDIA have increased by 9.58% YoY .
How the Earnings per Share (EPS) of ABBOTT INDIA have changed?
The Earnings Per Share (EPS) of ABBOTT INDIA has increased by 9.73 % YoY .
Check out Intrinsic Value of Peers of ABBOTT INDIA
Compare Stock Analytics of Peers of ABBOTT INDIA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
